: Asymptomatic Reactivation of JC Virus in Individuals Treated with Natalizumab As of July 24.

First, whether measurement of the viral load in blood and urine is an adequate surrogate marker of the activity of the virus in the central anxious system remains to be established. As the amount of sufferers with multiple sclerosis in whom PML evolves during natalizumab therapy proceeds to increase, these questions will demand urgent answers. Molecular monitoring of JC virus might allow early identification of individuals at an increased risk for PML in this population.. Yiping Chen, M.D., Ph.D., Evelyn Bord, B.S., Troy Tompkins, B.S., Janice Miller, B.S., Chen S. Tan, M.D., R. Philip Kinkel, M.D., Marion C. Stein, M.D., Raphael P. Viscidi, M.D., Long H. Ngo, Ph.D., and Igor J. Koralnik, M.D.: Asymptomatic Reactivation of JC Virus in Individuals Treated with Natalizumab As of July 24, 2009, progressive multifocal leukoencephalopathy , a deadly demyelinating disease of the central nervous program, had been reported in 13 patients with multiple sclerosis: 2 who were treated with a combination of natalizumab and interferon beta-1a 1-3 and 11 who received natalizumab monotherapy.4-7 One additional individual with Crohn’s disease who was treated with natalizumab died from PML.8 PML is caused by the reactivation of JC virus and affects sufferers with the acquired immunodeficiency syndrome or leukemia and recipients of organ transplants, but it had never been reported in a person with multiple sclerosis before natalizumab treatment was introduced.I’m all for people with vision problems. However now I have to put my most talented staff on this problem even before sorting out the fundamentals of transmitting details. Inside our iPhone-reverent age, the dismissal of EHR critics as Luddites can be supported by the reputation that technologies we once couldn’t imagine we have now can’t live without. However the assumption that EHR development will mirror the cell phone’s trajectory provides three notable flaws. The EHR is certainly touted as a cost-saving, quality-promoting device, though cost-conserving projections have already been debunked and data on quality are mixed.2 Although we’ve made improvement in individual safety only by carefully examining our errors, the risks posed by technology are expected to right themselves somehow.